Tuesday, June 23, 2015 3:08:50 PM
...But the FDA approval of the first a whole new kind of generic called a biosimilar earlier this year clears the way for a significant potential market for Momenta. Wheeler said the company has one partnership in place with Baxter International (NYSE: BAX) for a generic of the arthritis drug, Humira, the world’s top-selling drug which is expected to generate $14 billion in revenues for drugmaker AbbVie this year. It is also seeking a partner for other biosimilars in development...
Biosimilars are expected to be huge even more so than transition that occurred when generics were first released. Momenta should be a big player in that transition. Considering the big move it already has seen it could take awhile as some of that may already be priced in.
Marc Lichenfeld, Oxford Club/The Street.com/Oxford Income Letter says that he has identified five companies that will give their investors huge returns on/before October 20, 2015. Momenta is one of them.
It is easy to figure out what you believe. The difficulty lies in determining - is what you believe the truth.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM